Sujatha Menon

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance”.

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Annals of the Rheumatic Diseases(2022)10.1136/ard-2022-222259

N/A

5.2DataRank · unranked

206 citations

Maya H Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg +11 more

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Annals of the Rheumatic Diseases(2022)10.1136/ard-2022-222543

N/A

4.5DataRank · unranked

163 citations

Kunihiro Yamaoka, Yi‐Hsing Chen, Deepak L. Bhatt, Levent M Gunay, Naonobu Sugiyama +7 more